On May 1, 2018 Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, reported that two abstracts highlighting preclinical data on the use of its technology for regulation of immunocytokines have been selected for presentation at the 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper), taking place May 16-19, 2018, in Chicago, IL (Press release, Obsidian Therapeutics, MAY 1, 2018, View Source [SID1234525898]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentations, both taking place on Wednesday, May 16, 2018, are as follows:

Poster Title: Exogenous In Vitro and In Vivo Regulation of Interleukin-12 Secretion from T Cells Using Destabilizing Domain Technology
Presenter: Dexue Sun
Session Date/Time: Wednesday May 16, 2018, at 5:30 – 7:30 p.m. CT
Session title: Cancer – Immunotherapy, Cancer Vaccines I
Room: Stevens Salon C, D
Abstract number: 113

Poster Title: Dose dependent exogenous regulation of membrane bound Interleukin-15-Interleukin-15 receptor alpha fusion protein for adoptive T-cell therapy
Presenter: Christopher Reardon
Session Date/Time: Wednesday May 16, 2018, at 5:30 – 7:30 p.m. CT
Session title: Cancer – Targeted Gene & Cell Therapy I
Room: Stevens Salon C, D
Abstract number: 133

About Destabilizing Domains

Obsidian uses Destabilizing Domains (DDs) to enable pharmacologic regulation of protein activity for next-generation cell and gene therapies. Obsidian’s DDs are small, fully-human protein domains that confer conditional stability to a fused payload protein. In the absence of a specific small molecule ligand the fusion protein is rapidly degraded, whereas in the presence of the ligand, the fusion protein becomes stable and functional. Obsidian uses this approach to equip engineered cells with controllable functions that can be precisely tuned by the administration of non-immunosuppressive, small molecule medicines that are readily available and dispensed by the treating physician.

On May 1, 2018 Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, reported that it will announce financial results for the first quarter ended March 31, 2018 on May 8, 2018 before the Nasdaq market open (Press release, Loxo Oncology, MAY 1, 2018, View Source [SID1234525916]). At 8:00 a.m. ET that day, Loxo Oncology management will host a conference call to discuss these financial results, in addition to recent updates on development and corporate activities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial (877) 930-8065 (domestic) or (253) 336-8041 (international) and refer to conference ID 1979239. A replay will be available shortly after the conclusion of the call and archived on the company’s website for 30 days following the call.

On May 1, 2018 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that it will release its first quarter 2018 financial results on Tuesday, May 8, 2018, after the close of the U.S. financial markets (Press release, Syndax, MAY 1, 2018, View Source [SID1234525934]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with the earnings release, Syndax’s management team will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, May 8, 2018, to discuss the Company’s financial results and provide a general business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company’s website at www.syndax.com. Alternatively, the conference call may be accessed through the following:

Conference ID: 7087078
Domestic Dial-in Number: 1-855-251-6663
International Dial-in Number: 281-542-4259
Live webcast: View Source

For those unable to participate in the conference call or webcast, a replay will be available for 30 days on the Investors section of the Company’s website, www.syndax.com.

Michelle Mitchell OBE has been appointed as CEO of Cancer Research UK, replacing Sir Harpal Kumar who is due to stand down in the summer (Press release, Cancer Research UK, MAY 1, 2018, View Source [SID1234525907]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am delighted to be able to announce Michelle’s appointment as Cancer Research UK’s new CEO. She is an outstanding and seasoned charity leader, with the skill and ambition to lead the charity in the next phase of achieving our vision of 3 in 4 people surviving cancer by 2034." – Sir Leszek Borysiewicz, chairman of Cancer Research UK
Michelle Mitchell said: "It’s a privilege to be appointed as CEO of the world’s leading charity dedicated to beating cancer through research. Like many people, I have family who have been affected by cancer and I’m passionate about Cancer Research UK’s goal to speed up impact on survival. I have admired the work of the charity for many years, and I look forward to leading it as we embark on the next chapter of our critically important mission."

Michelle has been CEO of the MS Society since 2013. Under her leadership, there has been a 40% increase in access to effective MS treatments and she has developed a £100m research fundraising appeal.

Before joining the MS Society, Michelle’s previous leadership roles were as Director General of Age UK and Chair of the Fawcett Society.

Michelle is a non-executive director of NHS England, and has been a trustee of The King’s Fund and the Power to Change Trust.

Michelle has a BA in Economics, an MA in Politics and Administration and an International Executive Diploma from INSEAD. Michelle is an alumna of the Innovations in Government Programme at Harvard University JFK School and of the Strategic Perspectives in Non-profit Management programme at Harvard Business School.

On May 1, 2018 Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, reported the appointment of David Taylor, M.D., as Chief Medical Officer. Dr. Taylor brings over 35 years of extensive experience in medical research, drug and vaccine development and clinical trial management for government organizations, non-profits, academia and both private and public healthcare companies (Press release, Vaxart, MAY 1, 2018, View Source [SID1234525899]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Strengthening our leadership team with the appointment of David is an important milestone for Vaxart as we continue to advance our oral vaccine platform. Dr. Taylor is a drug discovery and development veteran with deep industry knowledge developing recombinant and enteric vaccines, with expertise in the design, execution and analysis of norovirus and influenza vaccine clinical trials," said Wouter Latour, chief executive officer of Vaxart. "We are pleased to welcome David and are confident his guidance will prove invaluable as we move our vaccine programs further in the clinic."

Prior to joining Vaxart, Dr. Taylor served as a senior medical officer of the drug and vaccine development global programs at PATH, where he developed clinical trial designs and executed studies for seasonal and universal flu vaccines and enteric vaccines. Earlier, he was senior medical director of vaccines at Takeda Vaccines, developing clinical trial plans for norovirus and dengue vaccines. Previously, Dr. Taylor served as chief medical officer at VaxInnate Corporation, where he focused on the development of recombinant vaccines for influenza and other infectious diseases, and chief medical officer and vice president of medical and safety at Salix Pharmaceuticals, where he developed Rifaximin (Xifaxan) for the treatment of traveller’s diarrhea and headed medical affairs and pharmacovigilance.

Before Salix, he was a research professor for the Department of International Health at Johns Hopkins Bloomberg School of Public Health. Dr. Taylor began his career as an epidemic intelligence service officer in the Enteric Disease Branch at the Centers for Disease Control and Prevention (CDC) and served 22 years in various capacities at research institutes in the United States Army including founder and chief of the Department of Clinical Trials and acting director for the Division of Communicable Diseases and Immunology at the Walter Reed Army Institute of Research.

Dr. Taylor earned his MSc. in Medical Parasitology from the London School of Hygiene and Tropical Medicine, M.D. from Harvard Medical School, D.M.S. from Dartmouth Medical School and B.S. in Biology from Kenyon College.

About Vaxart